NYSE:PHR - Phreesia Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $50.00
  • Forecasted Upside: -16.68 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$60.01
▼ -2.67 (-4.26%)
1 month | 3 months | 12 months
Get New Phreesia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PHR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PHR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$50.00
▼ -16.68% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for Phreesia in the last 3 months. The average price target is $50.00, with a high forecast of $70.00 and a low forecast of $30.00. The average price target represents a -16.68% upside from the last price of $60.01.
Buy
The current consensus among 12 contributing investment analysts is to buy stock in Phreesia.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/31/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/29/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/27/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/14/2021Needham & Company LLCBoost Price TargetBuy$60.00 ➝ $70.00High
i
12/14/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$33.00 ➝ $59.00Medium
i
12/14/2020Smith Barney CitigroupBoost Price Target$33.00 ➝ $59.00Low
i
12/10/2020Royal Bank of CanadaBoost Price TargetSector Perform$33.00 ➝ $51.00High
i
12/10/2020DA DavidsonBoost Price TargetBuy$35.00 ➝ $70.00High
i
Rating by H. Baade at DA Davidson
12/10/2020SVB LeerinkBoost Price TargetOutperform$37.00 ➝ $62.00High
i
12/9/2020Piper SandlerBoost Price TargetOverweight$35.00 ➝ $56.00High
i
12/9/2020Needham & Company LLCBoost Price TargetBuy$44.00 ➝ $60.00Medium
i
12/4/2020KeyCorpBoost Price TargetOverweight$37.00 ➝ $50.00High
i
11/10/2020StephensInitiated CoverageOverweight$50.00Medium
i
10/27/2020Needham & Company LLCInitiated CoverageBuy$44.00Low
i
10/23/2020Robert W. BairdBoost Price TargetPositive ➝ Outperform$32.00 ➝ $44.00Low
i
9/22/2020DA DavidsonInitiated CoverageBuy$35.00Low
i
Rating by H. Baade at DA Davidson
9/10/2020Raymond JamesBoost Price TargetOutperform$35.00 ➝ $36.00High
i
9/10/2020SVB LeerinkBoost Price TargetOutperform$31.00 ➝ $37.00Medium
i
Rating by Stephanie Davis at SVB Leerink LLC
9/9/2020Piper SandlerBoost Price TargetOverweight$34.00 ➝ $35.00Medium
i
9/3/2020Raymond JamesReiterated RatingBuyLow
i
7/14/2020CitigroupInitiated CoverageNeutral$32.00Low
i
6/10/2020Raymond JamesBoost Price TargetOutperform$30.00 ➝ $35.00High
i
Rating by John Ransom at Raymond James
6/9/2020KeyCorpBoost Price TargetOverweight$34.00 ➝ $37.00High
i
Rating by Donald Hooker at KeyCorp
5/20/2020KeyCorpBoost Price TargetOverweight$25.00 ➝ $34.00High
i
Rating by Donald Hooker at KeyCorp
5/15/2020GuggenheimInitiated CoverageBuy$31.00Medium
i
4/24/2020Raymond JamesLower Price TargetOutperform$33.00 ➝ $30.00Low
i
Rating by John Ransom at Raymond James
4/24/2020Robert W. BairdBoost Price TargetOutperform$26.00 ➝ $28.00Low
i
4/24/2020Wells Fargo & CompanyLower Price TargetOverweight$35.00 ➝ $30.00High
i
4/20/2020Royal Bank of CanadaInitiated CoverageSector Perform$21.00Low
i
4/13/2020SVB LeerinkInitiated CoverageOutperform$24.00Medium
i
4/8/2020Robert W. BairdLower Price TargetOutperform$31.00 ➝ $26.00High
i
Rating by Matthew Gillmor at Robert W. Baird
3/31/2020KeyCorpLower Price TargetOverweight$36.00 ➝ $25.00High
i
1/30/2020KeyCorpInitiated CoverageOverweight$36.00Low
i
1/8/2020Cantor FitzgeraldInitiated CoverageOverweight$32.00Medium
i
Rating by S. Halper at Cantor Fitzgerald
12/19/2019Raymond JamesInitiated CoverageOutperform$33.00Low
i
10/10/2019Robert W. BairdInitiated CoverageOutperform$31.00High
i
9/10/2019Piper Jaffray CompaniesSet Price TargetBuy$33.00Low
i
Rating by Sean Wieland at Piper Jaffray Companies
8/13/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$33.00Low
i
8/12/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$23.00High
i
8/12/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$33.00High
i
8/12/2019William BlairInitiated CoverageOutperform ➝ OutperformHigh
i
7/23/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$33.00Low
i
(Data available from 2/25/2016 forward)
Phreesia logo
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. It deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Stations that are on-site kiosks. The company's Phreesia Platform also provides a registration solution to automate patient self-registration; patient activation solution that enables providers to communicate with their patients through surveys, announcements, messaging, and health campaigns; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; clinical support solution that collects clinical intake and PRO data for approximately 25 specialties; appointments solution for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and life sciences, pharmaceutical, medical device, and biotechnology companies. Phreesia, Inc. has a strategic alliance agreement with Allscripts Healthcare, LLC. The company was founded in 2005 and is headquartered in New York, New York.
Read More

Today's Range

Now: $60.01
$59.12
$62.60

50 Day Range

MA: $68.31
$55.27
$80.61

52 Week Range

Now: $60.01
$16.01
$81.59

Volume

915,942 shs

Average Volume

462,904 shs

Market Capitalization

$2.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Phreesia?

The following sell-side analysts have issued stock ratings on Phreesia in the last twelve months: Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, DA Davidson, Guggenheim, KeyCorp, Needham & Company LLC, Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Smith Barney Citigroup, Stephens, SVB Leerink LLC, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for PHR.

What is the current price target for Phreesia?

14 Wall Street analysts have set twelve-month price targets for Phreesia in the last year. Their average twelve-month price target is $50.00, suggesting a possible downside of 16.8%. DA Davidson has the highest price target set, predicting PHR will reach $70.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $30.00 for Phreesia in the next year.
View the latest price targets for PHR.

What is the current consensus analyst rating for Phreesia?

Phreesia currently has 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PHR will outperform the market and that investors should add to their positions of Phreesia.
View the latest ratings for PHR.

What other companies compete with Phreesia?

How do I contact Phreesia's investor relations team?

Phreesia's physical mailing address is 432 Park Avenue South 12th Floor, New York NY, 10016. The company's listed phone number is 888-654-7473 and its investor relations email address is [email protected] The official website for Phreesia is www.phreesia.com.